Skip to main content
CANN GROUP LIMITED logo

CANN GROUP LIMITED — Investor Relations & Filings

Ticker · CAN ISIN · AU000000CAN2 LEI · 529900XX42XELLXVQE42 ASX Manufacturing
Open in API
Filings indexed 729 across all filing types
Latest filing 2022-10-30 Capital/Financing Update
Country AU Australia
Listing ASX CAN

About CANN GROUP LIMITED

https://www.canngrouplimited.com/

Cann Group Limited specializes in the cultivation, manufacture, and supply of medicinal cannabis products. The company focuses on providing pharmaceutical-grade cannabis for therapeutic use, utilizing advanced greenhouse technology and automated cultivation systems to ensure standardized quality and consistency. Its operations encompass the entire supply chain, from plant genetics and breeding to the production of finished medicinal products, including oils and dried flower. Cann Group serves healthcare professionals and patients through established distribution channels and maintains a focus on research and development to advance cannabinoid-based treatments. The company leverages large-scale production capabilities to meet growing demand in both domestic and international medicinal markets, emphasizing rigorous quality control and compliance with international pharmaceutical standards.

Recent filings

Filing Released Lang Actions
Cleansing Statement - Share Purchase Plan 1 page 20
Capital/Financing Update Classification · 95% confidence The document is a notice from Cann Group Limited regarding the intention to issue shares under a Share Purchase Plan (SPP). It references compliance with ASIC Corporations Instrument 2019/547 and the Corporations Act, and provides details about the share issuance and related disclosures. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an announcement about a capital raising activity through a share purchase plan, which fits the category of Capital/Financing Update (CAP). The document length is short and focused on the share issuance notice, not a full report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2022-10-30 English
Share Purchase Plan - offer opens 9 pages 349.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 31 October 2022 regarding the opening of a Share Purchase Plan (SPP) offer by Cann Group Limited. It includes detailed information about the SPP offer, eligibility, application process, key dates, and the purpose of the funds to be raised. The content focuses on fundraising activities through issuing new shares to existing shareholders. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a brief factsheet or a proxy solicitation. It is a capital raising announcement related to share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-10-30 English
Application for quotation of securities - CAN 6 pages 27.9KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, specifically relating to securities previously issued under an employee incentive scheme where transfer restrictions have ceased. It details the number and type of securities to be quoted, issue dates, and related information about the securities and issued capital. This is a formal announcement about the quotation of securities rather than a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, as it concerns the quotation of shares following the lifting of transfer restrictions on employee incentive scheme shares.
2022-10-27 English
Appendix 3H - Notification of Cessation of Securities 4 pages 479.9KB
Regulatory Filings Classification · 100% confidence The document is an Appendix 3H form, which is a notification to the ASX (Australian Securities Exchange) regarding the cessation of securities. It details the cessation of performance rights (equity securities) due to an employee leaving the company, causing the rights to lapse. The document includes specific ASX listing rules references (3.10.3E and 3.8A) and provides detailed information about the securities ceased, dates, and issued capital following the changes. This is a regulatory announcement about securities cessation, not a financial report, earnings release, or management discussion. It fits the category of a Regulatory Filing (RNS) as it is a compliance notification to the exchange about securities status changes and does not contain financial statements or management commentary.
2022-10-27 English
Quarterly Activities and Appendix 4C Cashflow Report 9 pages 298.3KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 27 October 2022 titled 'September 2022 Quarterly Activities Report and Appendix 4C'. It contains detailed financial data for the quarter ended 30 September 2022, including cash flow statements, operating activities, investing and financing activities, and commentary on business activities such as clinical trials, R&D, sales, and management changes. The presence of Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rules, confirms this is a quarterly report. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2022-10-26 English
Amended Quarterly Activities Report 10 pages 404.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report' and includes detailed financial data for the quarter ending 30 September 2022, such as cash flows from operating and investing activities, sales revenue, and R&D expenses. It also discusses operational updates, clinical trial progress, board and management changes, and a share purchase plan. The presence of substantive financial data and analysis for a quarter shorter than a fiscal year indicates this is a comprehensive interim/quarterly report. The document is about 15,000 characters long, so it is not a brief announcement or a certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2022-10-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.